Inclusion Criteria:
  -  Informed Consent as documented by signature
  -  Diagnosis of non-invasive (stage 0) or invasive (stage 1, 2 and 3A) breast adenocarcinoma
  -  Treatment with primary breast-sparing surgery (lumpectomy) and/or neoadjuvant (preoperative) or adjuvant (postoperative) chemotherapy or hormonal therapy
  -  Scheduled for postoperative radiotherapy at Ziekenhuis Oost-Limburg, Genk:
  -  Hypofractionated radiotherapy regimen (i.e. 16 daily fractions of 2.66 Gray to the whole breast followed by a boost of 5 fractions of 2.66 Gray to the tumor bed, 5x/week)     
Exclusion Criteria:
  -  Scheduled for postoperative radiotherapy at Jessa Hospital, Hasselt, Belgium
  -  Previous irradiation to the same breast
  -  Metastatic disease
  -  Concurrent chemotherapy
  -  Required use of bolus material to deliver radiotherapy (i.e material placed on the to-be- irradiated zone to modulate the delivered dose in order to ensure an optimal distribution of the radiation dose; mostly used for treatment of superficial tumors)
  -  Known or suspected non-compliance, drug or alcohol abuse
  -  Inability to follow the procedures of the study, e.g. due to language problems, psyschological disorders, dementia, etc. of the participant
  -  Seizure
  -  Disorders triggered by lighttake anticoagulants
  -  Hemorrhagic diatheses
  -  Pregnancy
  -  Suspected of carrying serious infectious disease
  -  HIV positive history
